9 Apr 2020 07:00
Silence Therapeutics Announces COVID-19 Partnership
09 April 2020
Silence Therapeutics supporting TIB Molbiol GmbH
to increase its production of COVID-19 PCR diagnostic testing kits
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has repurposed equipment in its Berlin site to produce critical reagents for COVID-19 PCR diagnostic test kits, which are currently in short supply. We are doing this work on a cost only basis for TIB Molbiol GmbH, based in Berlin, and believe the use of our specialist equipment will significantly increase their capacity to produce test kits on short notice and with high demand for global distribution.
Iain Ross, Executive Chairman at Silence Therapeutics, commented: "I would like to thank our innovative scientists for coming up with this approach and our lawyers at Cooley LLP for assisting us, pro-bono, to put this agreement in place with TIB Molbio. I confirm that this initiative does not impact Silence's core business and that any funds generated from this initiative will be donated to the fight against COVID-19."
For more information, please contact:
Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer
| Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
| Tel: +44 (0) 20 3709 5700 |
US IR Westwicke Peter Vozzo peter.vozzo@westwicke.com | Tel: +1 (443) 213-0505 |
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit: https://www.silence-therapeutics.com/